Cartesian Therapeutics (RNAC) Income from Continuing Operations (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Income from Continuing Operations of 26642000.0 for Q1 2026, down 31.95% year-over-year from 39150554.73 in Q1 2025, and up 66.06% quarter-over-quarter from 78506000.0 in Q4 2025.
Powered by 
Analysis
Cartesian Therapeutics (RNAC) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Income from Continuing Operations for 12 consecutive years, with 26642000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 31.95% year-over-year to 26642000.0; the TTM figure through Mar 2026 stood at 166840000.0 (down 77.84% YoY), while the FY2025 annual figure was 130295000.0, down 68.26% from the prior year.
- Income from Continuing Operations rose to 26642000.0 in Q1 2026 per RNAC's latest filing, from 78506000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 13352000.0 in Q2 2022 and bottomed at 196658000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 29819588.24 across 5 years, with a median of 20191000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 5275.19% — and 2023, when it tumbled 3437.15%.
- Cartesian Therapeutics' Income from Continuing Operations stood at 5893000.0 in 2022, then sank by 3437.15% to 196658000.0 in 2023, then surged by 87.14% to 25288000.0 in 2024, then plunged by 210.45% to 78506000.0 in 2025, then jumped by 66.06% to 26642000.0 in 2026.
- Business Quant data shows RNAC's Income from Continuing Operations at 26642000.0 in Q1 2026, 78506000.0 in Q4 2025, and 24605000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cartesian Therapeutics | 271.10 Mn | 271.10 Mn | - | -28.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -28.90 Mn |
| Mar 31, 2026 | -25.47 Mn |
| Dec 31, 2025 | -77.37 Mn |
| Sep 30, 2025 | -19.52 Mn |
| Jun 30, 2025 | -20.06 Mn |
| Mar 31, 2025 | -19.87 Mn |
| Dec 31, 2024 | -24.28 Mn |
| Sep 30, 2024 | -15.00 Mn |
| Jun 30, 2024 | 14.95 Mn |
| Mar 31, 2024 | -12.18 Mn |
| Dec 31, 2023 | -196.66 Mn |
| Sep 30, 2023 | -9.00 Mn |
| Jun 30, 2023 | -18.00 Mn |
| Mar 31, 2023 | -19.18 Mn |
| Dec 31, 2022 | 5.89 Mn |
| Sep 30, 2022 | -7.89 Mn |
| Jun 30, 2022 | 13.35 Mn |
| Mar 31, 2022 | 10.08 Mn |
| Dec 31, 2021 | 12.24 Mn |
| Sep 30, 2021 | -17.89 Mn |